ZYMFENTRA™(infliximab-dyyb), the first and only FDA-approved subcutaneous infliximab, now commercially available in the U.S.

ZYMFENTRA™ is the first FDA-approved subcutaneous infliximab for the treatment of moderately to severely active ulcerative colitis and moderately to severely active Crohn’s disease ZYMFENTRA™ is commercially available across the U.S. on March 15, 2024 JERSEY CITY, N.J., March 17, 2024…